Bukwang Pharmaceutical announced that it has entered into an agreement with Sanofi-Aventis Korea to co-promote an ARB class antihypertensive drugs, AprovelⓇ (active ingredient: irbesartan) and Co-aprovelⓇ (active ingredient: irbesartan + hydrochlorothiazide).
Starting from January 2020, Bukwang and Sanofi-Aventis Korea will co-promote to sell and market the products for hospitals and clinics nationwide. The annual sales of AprovelⓇ and Co-aprovelⓇ were recorded over 20 billion KRW in 2018 based on UBIST data.
AprovelⓇ(ingredient: irbesartan) is an angiotensin II receptor blocker (ARB) class antihypertensive drug. AprovelⓇshowed clinical efficacy in both hypertension and diabetic nephropathy, so it is considered to be the most effective treatment in patients with type 2 diabetes and hypertension. In addition, the combination of the ARB with diuretic agent, Co-aprovelⓇ(ingredient: irbesartan + hydrochlorothiazide) provides effective efficacy for patients who do not adequately controlled with monotherapy.
About 80% of Bukwang’s sales comes from original/branded products. The company has proven its ability to maintain and grow the sales of original/branded products even after generic introduction in the market. Bukwang expects overall revenue growth due to its recent activities in introducing new original products.
“Through the co-promotion of Aprovel with Sanofi-Aventis Korea, Bukwang aims to establish a solid footprint in circulatory/cardiovascular area and to achieve its goal to reach 200 billion KRW sales in 2020.”, Bukwang’s representative said.